Prescription Drug Price Transparency
Reporting Information for Manufacturers

Yes.

The New Drug and Price Growth provisions of the Act became active in January 2022 and are ongoing. Reporting requirements for these provisions operate on a rolling basis based on the date drug pricing events that meet statutory thresholds (introduction to market or price increase). Reports must be submitted within 60 days of the pricing event.

The Drugs of Substantial Public Interest provision of the Act went into effect in January 2024 and is ongoing. Reporting under this provision is based on lists published periodically by MDH. All lists posted by MDH are available on the Drugs of Substantial Public Interest Lists page. 

Yes. All manufacturers licensed in Minnesota need to register using the Rx Data Portal. For technical guidance on using the Rx Data Portal, including information on how to register and manage accounts, visit the Rx Data Portal Resources page.

For New Drug and Price Growth reporting, manufacturers are responsible for identifying their reporting obligations based on the statutory thresholds. MDH uses reference data to identify potential reporting obligations for compliance outreach.

For Drugs of Substantial Public Interest reporting, MDH publishes the lists of drugs for reporting online and will notify registered manufacturers of the drugs requiring reporting. All lists posted by MDH are available on the Drugs of Substantial Public Interest Lists page.

Manufacturers must use the Rx Data Portal for all submissions. Reporting templates are available for download within the portal.